As a major breakthrough in the pharmaceutical field, ultra long acting lipid-lowering drugs not only change the traditional treatment of hyperlipidemia, but also promote the prevention and treatment of cardiovascular and cerebrovascular diseases into a new stage. Liu Hong, chief physician of cardiac critical care at Fuwai Hospital, Chinese Academy of Medical Sciences, and visiting scholar at Johns Hopkins Hospital in the United States, told reporters that in recent years, ultra long acting lipid-lowering drugs have made significant progress in key areas such as RNA targeted therapy, gene editing technology, and new small molecule drugs. These innovative drugs have brought revolutionary changes to the treatment of hyperlipidemia by long-term regulation of key targets of cholesterol metabolism, such as PCSK9 and ANGPTL3. Ultra long acting lipid-lowering drugs have many advantages. Liu Hong said, "On the one hand, the frequency of using this drug 1-2 times a year greatly improves patient compliance, allowing patients to receive treatment more regularly. On the other hand, gene editing and RNA therapy are expected to achieve 'functional cure', fundamentally solving the problem of lowering blood lipids. ”However, these drugs also face certain challenges. Liu Hong believes that safety is the most critical issue, and the off target effects and long-term effects of gene editing need to be further validated to ensure the safety of medication for patients. In addition, most new therapies are expensive, such as gene editing single treatment costs or over a million dollars, which may limit their widespread application. Liu Hong stated that it is predicted that from 2025 to 2030, ultra long acting lipid-lowering drugs are expected to gradually replace traditional injections, and oral PCSK9 inhibitors and CRISPR therapy, with their unique advantages, may become the mainstream treatment methods in the future. (New Society)